In pediatric patients with confirmed autosomal dominant polycystic kidney disease (ADPKD) and nocturnal enuresis, what special considerations, contraindications, or treatment modifications are recommended?

Management of Nocturnal Enuresis in Pediatric ADPKD Patients

Use vasopressin analogues (such as desmopressin) with caution in children with ADPKD and nocturnal enuresis due to potential negative effects on cyst growth, and preferentially select alternative treatment options. 1

Key Contraindication: Vasopressin Analogues

The 2019 International Consensus Statement explicitly addresses this clinical scenario with a moderate-strength recommendation. The rationale is straightforward: since vasopressin antagonists (like tolvaptan) reduce cyst growth and slow eGFR decline in ADPKD, vasopressin analogues can reasonably be considered detrimental by promoting the opposite effect 1. Desmopressin, the most commonly used medication for nocturnal enuresis, works by mimicking vasopressin—the very hormone that drives cyst proliferation in ADPKD.

Clinical Reasoning

• Mechanistic concern: Vasopressin stimulates cyst epithelial cell proliferation and fluid secretion through V2 receptor activation
• Evidence level: While direct evidence is limited (evidence level X), the biological plausibility is strong given that vasopressin antagonism is the only FDA-approved disease-modifying therapy for adult ADPKD
• Frequency consideration: Nocturnal enuresis occurs at similar rates in children with ADPKD as in the general pediatric population 1, making this a common clinical dilemma

Alternative Treatment Approaches

When managing nocturnal enuresis in pediatric ADPKD patients, prioritize:

Non-Pharmacological Interventions (First-Line)

• Behavioral modifications: Scheduled nighttime voiding, fluid restriction 2-3 hours before bedtime
• Enuresis alarms: Conditioning therapy with moisture-sensing devices
• Bladder training exercises: Daytime voiding schedules to increase functional bladder capacity

Pharmacological Alternatives (If Needed)

• Anticholinergic agents: Oxybutynin or tolterodine for bladder instability (if overactive bladder component exists)
• Tricyclic antidepressants: Imipramine as second-line option (though less commonly used in modern practice due to side effect profile)

Important Caveats

Do not withhold treatment entirely—nocturnal enuresis significantly impacts quality of life, self-esteem, and social development in children. The goal is to avoid vasopressin analogues specifically, not to leave the condition untreated.

Reassess the diagnosis: Ensure enuresis is truly primary nocturnal enuresis and not secondary to:

• Urinary tract infection (more common with structural kidney abnormalities)
• Polyuria from early concentrating defects in ADPKD
• Hypertension-related nocturia (20% of pediatric ADPKD patients have hypertension) 1

Additional ADPKD-Specific Considerations

While managing enuresis, maintain the broader ADPKD care framework:

• High water intake: The guideline recommends high water intake to slow ADPKD progression 1, which may paradoxically worsen enuresis. Balance this by concentrating fluid intake during daytime hours
• Monitor blood pressure: Annual BP monitoring is essential, with ambulatory BP monitoring for those ≥5 years old with height >120 cm 2
• Avoid NSAIDs: For any pain management needs, as chronic NSAID use can accelerate kidney disease 1

Practical Algorithm

1. Confirm diagnosis: Rule out secondary causes (UTI, diabetes, concentrating defect)
2. Initiate behavioral therapy: First-line for all patients
3. If pharmacotherapy needed: Select anticholinergics or other alternatives—explicitly avoid desmopressin
4. Counsel families: Explain the ADPKD-specific rationale for avoiding standard first-line therapy
5. Coordinate care: Ensure pediatric nephrologist is aware of enuresis management plan

This approach prioritizes long-term kidney outcomes (morbidity) while still addressing the quality-of-life impact of nocturnal enuresis.